| __timestamp | Grifols, S.A. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1656170000 | 205018000 |
| Thursday, January 1, 2015 | 2003565000 | 392709000 |
| Friday, January 1, 2016 | 2137539000 | 299694000 |
| Sunday, January 1, 2017 | 2166062000 | 397061000 |
| Monday, January 1, 2018 | 2437164000 | 434100000 |
| Tuesday, January 1, 2019 | 2757459000 | 782200000 |
| Wednesday, January 1, 2020 | 3084873000 | 1119900000 |
| Friday, January 1, 2021 | 2970522000 | 2437500000 |
| Saturday, January 1, 2022 | 3832437000 | 1560400000 |
| Sunday, January 1, 2023 | 4269276000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Over the past decade, Regeneron Pharmaceuticals, Inc. and Grifols, S.A. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Grifols' cost of revenue surged by approximately 158%, peaking at over $4.3 billion in 2023. In contrast, Regeneron demonstrated a more conservative growth of around 785%, reaching nearly $1.8 billion in the same year. This stark difference highlights Grifols' expansive operational scale compared to Regeneron's strategic cost management. Notably, Regeneron's cost efficiency improved significantly post-2019, with a remarkable 212% increase by 2021, reflecting its adaptive strategies in a dynamic market. As the pharmaceutical industry evolves, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
Cost of Revenue: Key Insights for Eli Lilly and Company and Grifols, S.A.
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Grifols, S.A.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Grifols, S.A.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Biogen Inc.'s Expenses
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Grifols, S.A.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Cost of Revenue: Key Insights for Incyte Corporation and Grifols, S.A.
Cost of Revenue Trends: Jazz Pharmaceuticals plc vs Grifols, S.A.
Cost of Revenue Trends: Grifols, S.A. vs ADMA Biologics, Inc.
Grifols, S.A. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored